OrbiMed’s Janux Therapeutics JANX Stock Holding History

OrbiMed’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.7M	Sell	983,600 -970,826	-50%	-$13.3M	0.27%	71
2025 Q4	$27M	Buy	1,954,426 +188,326	+11%	+$4.43M	0.55%	51
2025 Q3	$43.2M	Buy	1,766,100 +555,800	+46%	+$13.5M	1.01%	34
2025 Q2	$28M	Buy	1,210,300 +451,734	+60%	+$11.9M	0.7%	38
2025 Q1	$20.5M	Hold	758,566	–	–	0.49%	43
2024 Q4	$40.6M	Sell	758,566 -500,000	-40%	-$26.4M	0.84%	35
2024 Q3	$57.2M	Sell	1,258,566 -1,721,262	-58%	-$74.9M	1.04%	28
2024 Q2	$125M	Sell	2,979,828 -1,295,725	-30%	-$60.8M	2.46%	10
2024 Q1	$161M	Buy	4,275,553 +957,626	+29%	+$20.9M	2.95%	8
2023 Q4	$35.6M	Hold	3,317,927	–	–	0.71%	50
2023 Q3	$33.4M	Buy	3,317,927 +481,541	+17%	+$5.55M	0.71%	53
2023 Q2	$33.7M	Hold	2,836,386	–	–	0.61%	52
2023 Q1	$34.3M	Hold	2,836,386	–	–	0.67%	47
2022 Q4	$37.4M	Hold	2,836,386	–	–	0.71%	51
2022 Q3	$38.4K	Hold	2,836,386	–	–	0.71%	53
2022 Q2	$34.6K	Hold	2,836,386	–	–	0.63%	50
2022 Q1	$40.7M	Hold	2,836,386	–	–	0.66%	45
2021 Q4	$56M	Sell	2,836,386 -630,000	-18%	-$13.2M	0.72%	46
2021 Q3	$75M	Hold	3,466,386	–	–	0.82%	37
2021 Q2	$86.5M	Buy	+3,466,386	New	+$77.2M	0.87%	37

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OrbiMed's JANX Position: Q1 2026 in Review

OrbiMed reduced its Janux Therapeutics (JANX) stake by 50% in Q1 2026, selling an estimated $13.3M and leaving 983,600 shares worth $13.7M. The position accounts for 0.27% of the portfolio, ranked #71.

OrbiMed first reported a position in JANX in Q2 2021 and has held it in 20 quarters since. The position peaked at $161M in Q1 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

OrbiMed held 983,600 shares of Janux Therapeutics worth $13.7M as of Q1 2026.
OrbiMed sold 970,826 Janux Therapeutics shares in Q1 2026, an estimated $13.3M.
Janux Therapeutics made up 0.27% of OrbiMed's portfolio in Q1 2026, its #71 holding.
OrbiMed first reported a position in Janux Therapeutics in Q2 2021 and has held it in 20 quarters since.
OrbiMed's Janux Therapeutics position peaked at $161M in Q1 2024.
190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.